Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in Schizophrenia
NCT02874573Phase 1Unknown
- Start
- Sep 2016
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tocilizumab in schizophrenia and schizoaffective disorder. Primary endpoint: Change in Cognition at 12 weeks. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02874573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874573.